+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Stereotactic vacuum-assisted breast biopsy in 268 nonpalpable lesions

Stereotactic vacuum-assisted breast biopsy in 268 nonpalpable lesions

La Radiologia Medica 113(1): 65-75

We evaluated the reliability of stereotactic vacuum-assisted breast biopsies (VAB) from our personal experience. Between January 2003 and December 2005, 268 patients underwent VAB with an 11-gauge probe at our institution. Inclusion criteria were nonpalpable lesions, undetectable by ultrasound and suspected at mammography (microcalcifications, circumscribed mass, architectural distortion), for which cytology and/or core biopsy could not provide a definite diagnosis. Lesion mammographic patterns were microcalcifications in 186 cases (77.5%), mostly localised clusters (130/186: 70%); circumscribed mass with or without microcalcifications in 36 cases (15%) and architectural distortion with or without microcalcifications in 18 cases (7.5%). On the basis of the Breast Imaging Reporting and Data System (BI-RADS) classification, 16 cases (7%) were graded as highly suspicious for malignancy (BI-RADS 5), 81 (34%) as suspicious for malignancy (BI-RADS 4b), 97 (40%) as indeterminate (BI-RADS 4a) and 46 (19%) as probably benign (BI-RADS 3). Lesion size was 20 mm in only 38 cases (16%), 30 of which appeared as microcalcifications. In 28/268 lesions (10.5%) the biopsy could not be performed (nonidentification of the lesion; inaccessibility due to location or breast size). In 12/240 (5%) biopsies, the sample was not representative. Pathology revealed 100/240 (42%) malignant or borderline lesions and 140/240 (58%) benign lesions. Among the malignant lesions, 16/100 (16%) were invasive carcinoma [infiltrating ductal carcinoma (IDC) or infiltrating lobular carcinoma (ILC)], 13/100 (13%) were microinvasive (T1mic), 35/100 (35%) were ductal carcinoma in situ (DCIS), 9/100 (9%) were lobular carcinoma in situ (CLIS). Among the borderline lesions, 27/100 (27%) were atypical epithelial hyperplasia [atypical ductal hyperplasia (ADH) or atypical lobular hyperplasia (ALH)]. In 9/100 surgically treated lesions (9%), there was discordance between the microhistological findings of VAB and the pathological results of the surgical procedure: 8/9 were underestimated by VAB (four ADH vs. DCIS, three DCIS vs. IDC, one ADH vs. IDC), and 1/9 was overestimated (T1mic vs. DCIS). Complications following VAB occurred in 9/240 patients (3.7%). In our experience, VAB showed fair reliability in the diagnosis of nonpalpable breast lesions despite a portion of failed (10.5%), nonsignificant (5%) procedures and underestimated lesions (9%).

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 055923471

Download citation: RISBibTeXText

PMID: 18338128

DOI: 10.1007/s11547-008-0226-0

Related references

Breast biopsy for mammographically detected nonpalpable lesions using a vacuum-assisted biopsy device Mammotome and upright-type stereotactic mammography unit without a digital imaging system experience of 5 biopsies. 2014

Breast biopsy for mammographically detected nonpalpable lesions using a vacuum-assisted biopsy device (Mammotome) and upright-type stereotactic mammography unit without a digital imaging system: experience of 500 biopsies. Breast Cancer 21(2): 123-127, 2016

Efficacy and cost-effectiveness of stereotactic vacuum-assisted core biopsy of nonpalpable breast lesions: analysis of 602 biopsies performed over 5 years. La Radiologia Medica 116(3): 477-488, 2011

Nonpalpable breast cancer: percutaneous diagnosis with 11- and 8-gauge stereotactic vacuum-assisted biopsy devices. Radiology 219(3): 793-796, 2001

Complete removal of nonpalpable breast malignancies with a stereotactic percutaneous vacuum-assisted biopsy instrument. Journal of the American College of Surgeons 189(3): 237-240, 1999

Intraoperative ultrasonographically guided excisional biopsy or vacuum-assisted core needle biopsy for nonpalpable breast lesions. Annals of Surgery 238(5): 738-742, 2003

Duration time of vacuum-assisted biopsy for nonpalpable breast masses: comparison between stereotactic and ultrasound-guided procedure. Tumori 97(4): 517-521, 2012

On the diagnostic accuracy of stereotactic vacuum-assisted biopsy of nonpalpable breast abnormalities. Results in a consecutive series of 769 procedures performed at the Trento Department of Breast Diagnosis. Tumori 98(1): 113-118, 2012

Vacuum-assisted breast biopsy in nonpalpable solid breast lesions without microcalcifications: the Greek experience. Diagnostic and Interventional Radiology 14(3): 127-130, 2008

Vacuum-assisted breast biopsy on digital stereotaxic table of nonpalpable lesions non-recognisable by ultrasonography. European Radiology 12(3): 638-645, 2002

Digital breast tomosynthesis-guided vacuum-assisted breast biopsy: initial experiences and comparison with prone stereotactic vacuum-assisted biopsy. Radiology 274(3): 654-662, 2015

Mucocele-like lesions of the breast: management after diagnosis on ultrasound guided core biopsy or stereotactic vacuum-assisted biopsy. Gynecologie, Obstetrique and Fertilite 38(7-8): 455-459, 2010

Can galactography-guided stereotactic, 11-gauge, vacuum-assisted breast biopsy of intraductal lesions serve as an alternative to surgical biopsy?. European Radiology 19(12): 2878-2885, 2011

Breast biopsy for mammographically detected non-palpable lesions using a vacuum-assisted biopsy device (Mammotome) and an upright-type stereotactic mammography unit. Japanese Journal of Clinical Oncology 31(11): 527-531, 2002

Stereotactic vacuum-assisted core biopsy results for non-palpable breast lesions. Asian Pacific Journal of Cancer Prevention 15(13): 5171-5174, 2015